Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
Santiago Terán(Hospital Universitario 12 De Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Eva Ciruelos, Manuel Alva(Hospital Universitario 12 De Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Macarena Rey-Cárdenas(Hospital Universitario 12 De Octubre), Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Laura Lema(Hospital Universitario 12 De Octubre), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 4
Related Papers
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
|Journal of Clinical Oncology|2006|149
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <i>V600E</i> mutation
|The Journal of Experimental Medicine|2019|136